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Anja Berger1, Sandra-Annika Quast1, Michael Plo¨tz1, Nicholas-Frederik Kuhn1, Uwe Trefzer1 and
Ju¨rgen Eberle1
Mutated BRAF represents a critical oncogene in melanoma, and selective inhibitors have been approved for
melanoma therapy. However, the molecular consequences of RAF inhibition in melanoma cells remained largely
elusive. Here, we investigated the effects of the pan-RAF inhibitor L-779,450, which inhibited cell proliferation
both in BRAF-mutated and wild-type melanoma cell lines. It furthermore enhanced apoptosis in combination
with the death ligand tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and overcame TRAIL
resistance in melanoma cells. Enhanced apoptosis coincided with activation of mitochondrial pathways, seen by
loss of mitochondrial membrane potential and release of cytochrome c, Smac (second mitochondria–derived
activator of caspases), and apoptosis-inducing factor (AIF). Subsequently, caspase-9 and -3 were activated.
Apoptosis induction by L-779,450/TRAIL was prevented by Bcl-2 overexpression and was dependent on Bax. Thus,
activation of Bax by L-779,450 alone was demonstrated by Bax conformational changes, whereas Bak was not
activated. Furthermore, the BH3-only protein Bim was upregulated in response to L-779,450. The significant roles
of Smac, Bax, and Bim in this setting were proven by small interfering RNA (siRNA)-mediated knockdown
experiments. L-779,450 also resulted in morphological changes indicating autophagy confirmed by the autophagy
marker light chain 3-II (LC3-II). The pro-apoptotic effects of L-779,450 may explain the antitumor effects of RAF
inhibition and may be considered when evaluating RAF inhibitors for melanoma therapy.
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INTRODUCTION
The high mortality of metastatic melanoma strongly relates to
its pronounced resistance to chemotherapy as well as to an
antitumor immune response (Garbe and Leiter, 2009). This is
explained by defects in pro-apoptotic signaling, suggesting the
overcoming of melanoma apoptosis deficiency as a
predominant therapeutic target (Eberle et al., 2007).
Mitogen-activated protein kinase (MAPK) pathways,
initiated via Ras and RAF, have important roles in tumor
development (Gray-Schopfer et al., 2005). The signaling
cascade via MAPK/extracellular signal-regulated kinase (ERK)
kinase (MEK) and ERK leads to phosphorylation of multiple
target proteins, which drive the regulation of gene expression,
cell differentiation, proliferation, and survival (Inamdar et al.,
2010). Three RAF isoforms (A, B, and C) have been reported,
which exert distinct roles in different cells (Maurer et al.,
2011). For melanoma, activating mutations in N-Ras
(10–25%) and BRAF (40–60%) appear to be of particular
interest (Davies et al., 2002; Sullivan and Flaherty, 2012). The
high frequency of the BRAF(V600E) mutation resulted in the
development of selective BRAF inhibitors, partially already
approved for melanoma therapy (Flaherty et al., 2010;
Chapman et al., 2011; Hauschild et al., 2012; Long et al.,
2012; Sosman et al., 2012). However, the significance of RAF
inhibitors in the regulation of apoptosis in melanoma cells has
not been sufficiently explored.
In apoptosis control, extrinsic proapoptotic pathways are
initiated by binding of death ligands as tumor necrosis
factor-a, CD95L/FasL, and tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) to their respective death
receptors, leading to the formation of death-inducing signal-
ing complexes and activation of initiator caspase-8 (Krammer
et al., 2007). On the other hand, intrinsic apoptosis pathways
may be initiated by cellular dysregulation and DNA damage
and may result in pro-apoptotic mitochondrial activation. Key
events are depolarization of the mitochondrial membrane
potential (Dcm) and mitochondrial outer membrane
permeabilization, leading to the release of cytochrome c,
Smac (second mitochondria–derived activator of caspases),
and AIF (apoptosis-inducing factor). Whereas cytochrome c
activates initiator caspase-9, Smac functions as an antagonist
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of cellular inhibitor of apoptosis proteins (e.g. X-linked
inhibitor of apoptosis (XIAP) and survivin), which themselves
prevent effector caspase activity (Tait and Green, 2010).
Mitochondrial apoptosis pathways are critically controlled
by the family of Bcl-2 proteins, which encloses anti-apoptotic
(e.g. Bcl-2 and Mcl-1), pro-apoptotic multidomain (Bax and
Bak), and pro-apoptotic BH3-only proteins (e.g. Bid and Bim)
(Chipuk et al., 2010). Initiator caspases activated in both
pathways may drive the processing and activation of the main
effector caspase-3, which itself cleaves various death substrates
to set apoptosis into work (Fischer et al., 2003). Mitochondrial
pathways may also be activated by death ligands via caspase-8-
mediated processing and activation of Bid (Li et al., 1998).
The death ligand TRAIL represents an additional therapeutic
strategy and selectively induces apoptosis in cancer cells via
TRAIL receptors DR4 and DR5 (Newsom-Davis et al., 2009).
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Figure 1. Antiproliferative effects by L-779,450. (a) Levels of phosphorylated extracellular signal-regulated kinase (pERK) and total ERK were determined by
western blotting in human melanoma cell lines treated for 24 hours with L-779,450 (0.1–50mM): A-375, A-375-TS (V600E), and MeWo (BRAF-wild type (WT)).
Two independent experiments revealed comparable results; equal loading was proven by glyceraldehyde dehydrogenase (GAPDH). (b) Apoptosis (% of sub-G1
cells) was determined in response to L-779,450 (5–40mM; 24 hours) in A-375, Mel-HO-TS, Mel-2a, MeWo, and SK-Mel-13. Cytotoxicity (lactate dehydrogenase
(LDH) release) was determined in parallel (below). Here, values of non-treated cells were set to 1. (c) Apoptosis was also determined at 48 and 72 hours
(L-779,450, 10mM). (b, c) Means and SDs of triplicates; at least two independent experiments. (d) Cell cycle analyses of human melanoma cell lines: open graphs,
L-779,450-treated (10mM, 24 hours); filled graphs, dimethyl sulfoxide (DMSO)-treated controls. (e) Growth curves determined in real time of melanoma cell lines
treated with L-779,450 (5–20mM) were compared with controls (0). Means and SDs (at 48 hours) of triplicate determinations are shown; two independent
experiments were performed. Statistical significance is indicated (*Po0.05), when comparing L-779,450 and DMSO-treated cells.
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In melanoma cells and tissue samples, we have previously
shown functional activity of TRAIL receptors (Kurbanov et al.,
2005); however, some melanoma cell lines revealed perma-
nent TRAIL resistance and others developed inducible resi-
stance upon TRAIL treatment (Kurbanov et al., 2007). Inducible
resistance was related to the downregulation of TRAIL
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receptors, initiator caspases, and pro-apoptotic Bcl-2 proteins
(Zhang et al., 2006; Kurbanov et al., 2007), whereas the causes
of permanent resistance in melanoma remained elusive.
The correlation of MAPK activity and resistance to TRAIL-
induced apoptosis in melanoma cells had already been shown
in a previous study when applying an MEK inhibitor (Zhang
et al., 2003). Here, we prove the strong relation of RAF
inhibition and apoptosis regulation in melanoma cells. As
shown by small interfering RNA (siRNA)-mediated knockdown
studies, the sensitization for TRAIL was particularly based on
Bax activation and on upregulation of Bim in response to the
inhibitor alone. This resulted in the activation of mitochondrial
apoptosis pathways, particularly based on the release of Smac.
RESULTS
Direct effects of L-779,450
The pan-RAF inhibitor L-779,450 was applied for understand-
ing the relations of RAF inhibition and apoptosis regulation in
melanoma cells. Strong and dose-dependent phosphorylated
ERK (pERK) downregulation was seen by L-779,450 in the
BRAF(V600E)-mutated, TRAIL-sensitive melanoma cell line
A-375, as well as in TRAIL-resistant A-375-TS. Reduced sensiti-
vity of A-375-TS may be explained by its selection for TRAIL
resistance. In contrast, only incomplete pERK downregulation
was seen in the BRAF-wild-type (WT) melanoma cell line
MeWo, even at high concentrations (Figure 1a). Downregulation
of pERK largely remained without direct effect on apoptosis and
cytotoxicity in melanoma cells up to 72 hours (Figure 1b and c).
However, partial G1 arrest and depletion of S-phase cells
were seen at 24 hours in four BRAF-mutated melanoma cell
lines (A-375, Mel-HO, Mel-2a, and SK-Mel-28) as well as in
their TRAIL-selected derivatives A-375-TS and Mel-HO-TS.
G1 arrest was also seen in two N-Ras-mutated, BRAF-WT cell
lines (SK-Mel-103 and SK-Mel-147), whereas another BRAF-
WT cell line (MeWo) and the BRAF-mutated cell line SK-Mel-
13 did not respond (Figure 1d). Treatment with L-779,450
resulted in dose-dependent decrease of cell numbers, as
determined in real time (Figure 1e).
Sensitization for death ligand–induced apoptosis
The sensitivity of melanoma cell lines for the death ligand
TRAIL had been described in previous studies (Kurbanov et al.,
2005, 2007; Berger et al., 2011). The effects of L-779,450 on
TRAIL sensitivity were investigated here in melanoma cell
lines with high TRAIL sensitivity (A-375 and SK-Mel-147),
moderate sensitivity (Mel-HO, SK-Mel-13, and SK-Mel-28),
and permanent resistance (MeWo, Mel-2a, and SK-Mel-103),
as well as in TRAIL-selected cell lines with acquired resistance
(A-375-TS and Mel-HO-TS). Despite only moderate direct
effects of L-779,450 on apoptosis, it strongly enhanced TRAIL-
induced apoptosis in sensitive melanoma cells and overruled
TRAIL resistance in Mel-2a, SK-Mel-103, A-375-TS, and Mel-
HO-TS. At 24 hours, 16–35% apoptosis induction was
obtained, whereas cytotoxicity remained largely unaffected.
BRAF-WT cells MeWo as well as BRAF-mutated cells
SK-Mel-13 revealed no enhancement, not even at 72 hours
after treatment (Figure 2a, b, and e).
Morphologic changes characteristic for apoptosis became
evident by bisbenzimide nuclear staining. Thus, nuclear frag-
mentation and chromatin condensation were seen at 24 hours
in 18–30% of A-375 and A-375-TS cells (Figure 2c and d). The
strong impact of induced apoptosis on cell proliferation was
visualized by real-time cell analysis. Thus, complete detach-
ment of cells was seen in A-375 and A-375-TS already at
36 hours in response to L-779,450/TRAIL (20 ng ml 1;
Figure 2f). Treatment with the MEK inhibitor U0126 (20mM)
was applied for comparison and revealed a similar picture.
Thus, it also enhanced TRAIL-induced apoptosis in A-375,
A-375-TS, and Mel-HO but not in MeWo (Figure 2g–i). Also,
treatment with the selective BRAF(V600E) inhibitor vemurafe-
nib/PLX4032 resulted in comparable effects. Thus, PLX4032
similarly induced a G1 arrest and enhanced TRAIL-induced
apoptosis in A-375, A-375-TS, and Mel-HO (Figure 2j and k).
Activation of mitochondrial pro-apoptotic pathways
Involvement of caspases and Bid was investigated by monitor-
ing activated cleavage products and loss of proforms, respec-
tively. Processing of the extrinsic initiator caspase-8 and of Bid
was already seen in A-375 and A-375-TS melanoma cells in
response to TRAIL (16 hours), despite lacking TRAIL respon-
siveness of A-375-TS. This was evident by caspase-8 cleavage
products (41 and 43 kDa) as well as by loss of caspase-8 and
Bid proforms (57 and 22 kDa). This processing was, however,
not enhanced by the combination with L-779,450 (Figure 3a).
Decreased levels of the proform of the intrinsic initiator
caspase-9 (47 kDa) were seen in A-375 in response to
L-779,450þ TRAIL but not in A-375-TS. Thus, initiator cas-
pases could not (fully) explain enhanced apoptosis (Figure 3a).
On the other hand, processing of the main effector caspase-3
was significantly enhanced by L-779,450/TRAIL, seen by its
Figure 2. Sensitization of melanoma cells for tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-induced apoptosis. (a) Percentages of
apoptotic cells (sub-G1) were determined in human melanoma cell lines at 24 hours in response to L-779,450 (10–40mM) and TRAIL. Examples are shown in insets.
(b) Cytotoxicity (lactate dehydrogenase (LDH) release) was determined in parallel. Values of non-treated cells are set to 1. (c) Photographs (magnification 1:400)
after bisbenzimide (Hoechst 33258) staining: TRAIL-sensitive A-375 and TRAIL-resistant A-375-TS cells treated for 24 hours with 10mM L-779,450/TRAIL. White
arrows show examples of fragmented or condensed nuclei. (d) Quantitative evaluation of cells with fragmented nuclei and/or condensed chromatin. (e) MeWo
cells were treated also for 48 and 72 hours (percentages of sub-G1 cells). (f) Growth curves (real time) of A-375 and A-375-TS treated with TRAIL, L-779,450 (5mM),
or the combination were compared with non-treated controls. (g) Percentages of apoptotic cells (sub-G1) were determined in response to 20mM U0126±TRAIL.
(h) Cell cycle analyses of A-375 and MeWo treated with U0126 (20mM, 24 hours, open graphs), as compared with dimethyl sulfoxide (DMSO) controls (filled
graphs). (i) Growth curves of A-375 treated with U0126 (20mM) and/or TRAIL (means and SDs of triplicate determinations). (j) Percentages of apoptotic cells (sub-
G1) were determined in response to PLX4032 (3, 10, and 40mM)±TRAIL. (k) Cell cycle analyses of A-375, A-375-TS, and Mel-HO treated with PLX4032 (10mM,
2 hours, open graphs), as compared with DMSO controls (filled graphs). Always, two to three independent experiments revealed highly comparable results.
Statistical significance (*Po0.05) is indicated, when comparing L-779,450/TRAIL treatment with TRAIL alone. HOECHST/bisbenzimide staining.
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cleavage products of 15, 17, and 20 kDa (Figure 3a). The
decisive role of caspases was further demonstrated by the
pancaspase inhibitor Q-VD-OPh, which completely abrogated
apoptosis induction by L-779,450/TRAIL (Figure 3b).
Lacking enhancement of caspase-8 and Bid processing
suggested a role of Smac, which may antagonize cIAPs and
thus activate caspase-3. Confirming the activation of mito-
chondrial apoptosis pathways, strong decrease of the mito-
chondrial membrane potential Dcm was seen at 24 hours in
A-375 (490%) and in A-375-TS (50%) in response to
L-779,450/TRAIL. In comparison, L-779,450 alone remained
without effect on Dcm, and a response to TRAIL was seen in
only 16% of A-375 (Figure 4a). Loss of Dcm appeared as in
parallel to apoptosis induction, as not seen at 2 and 4 hours
(data not shown).
Finally proving the activation of mitochondrial apoptosis
pathways, both A-375 and A-375-TS revealed strong release of
mitochondrial apoptogenic factors (cytochrome c, AIF, and
Smac) upon L-779,450/TRAIL treatment. This effect was
already seen at 3 hours, before any apoptosis was induced
(Figure 4b) and was still seen at 16 hours (data not shown).
Mitochondrial release thus appeared as an early and initial
effect. Smac represented a suitable candidate for overcoming
the apoptosis blockade through cIAPs in melanoma cells. In
agreement, siRNA-mediated Smac knockdown decreased
apoptosis by L-779,450/TRAIL in A-375 by 60% (Figure 4c).
Decisive roles of Bcl-2 and Bax
The significance of mitochondrial apoptosis pathways was
further underscored by decisive roles of Bcl-2 and Bax. Thus,
Bcl-2 stable overexpression in A-375 (A-375-Bcl-2) comple-
tely prevented apoptosis induction by L-779,450/TRAIL
(20 ng ml1; Figure 5a) and also abolished loss of Dcm
(Figure 5b). Because of preferential binding of Bcl-2 to Bax,
this suggested a particular role of the Bax pathway.
The roles of Bax and Bak were distinguished in a BRAF-WT,
K-Ras-mutated HCT-116 colon carcinoma cell model consist-
ing of BaxþBakþ parental cells, Bax knockout, Bak knock-
down, and double knockdown cells. Comparable apoptosis
induction was seen at 24 hours in the parental and the Bak
knockdown cells, whereas apoptosis was completely
abrogated by Bax knockout (Figure 5c). Bax dependency
was also proven in A-375 melanoma cells by siRNA
strategies for Bax and Bak, respectively. Again, only the Bax
knockdown resulted in resistance to TRAIL as well as to
L-779,450/TRAIL, whereas Bak knockdown remained without
effect (Figure 5d).
The critical role of Bax was further investigated by
N-terminus–specific antibodies indicative for Bax activation.
Of note, significant Bax activation was seen in A-375 and
A-375-TS already in response to L-779,450 alone, which itself
did not induce apoptosis. This again appeared as an initial
effect already at 2 hours. In contrast, TRAIL treatment
remained without effect on Bax activation, and no activation
was seen for Bak, as determined by a Bak-NT antibody
(Figure 5e). Thus, Bax activation through L-779,450 did not
trigger apoptosis by itself but enhanced TRAIL sensitivity of
melanoma cells.
Induced Bim expression and autophagy by L-779,450
For further understanding the enhancement of apoptosis, the
expression of multiple apoptosis regulators was investigated in
Mel-HO, A-375, and A-375-TS at 16 hours of treatment. No
significant changes in response to L-779,450 were obtained by
western blotting for Bcl-2, Mcl-1, Bax, Bak, survivin, or XIAP
or by flow cytometry for TRAIL receptors DR4 and DR5 (data
not shown). However, significant upregulation was found for
the BH3-only protein BimEL, which may contribute to induc-
tion of mitochondrial, proapoptotic pathways (Figure 6a).
TRAIL alone or in combination with L-779,450 did not affect
Bim expression (Figure 6b). The significant role of Bim for
L-779,450/TRAIL-mediated apoptosis was shown again by
siRNA-mediated Bim knockdown in A-375, which abolished
Bim upregulation and decreased apoptosis by 40%
(Figure 6c).
In course of L-779,450 treatment, responsive melanoma
cells revealed consistent morphological changes, as large
vacuoles strongly indicative of autophagy (Figure 6d). Again,
these changes were not seen in MeWo and SK-Mel-13. Further
substantiating autophagy, the marker light chain 3-II (LC3-II)
was significantly upregulated upon treatment with L-779,450
(Figure 6e). Thus, apoptosis sensitization for TRAIL by activa-
tion of proapoptotic mitochondrial pathways via Bim and Bax
as well as induced autophagy appeared as characteristic for
the melanoma cell response to RAF inhibition.
DISCUSSION
MAPK pathways initiated by Ras/RAF have decisive roles in
melanoma (Davies et al., 2002; Jin et al., 2012; Mann et al.,
2012). Thus, selective inhibitors for mutated BRAF as
vemurafenib and dabrafenib have been approved or are in
clinical trials (Flaherty et al., 2010; Chapman et al., 2011;
Hauschild et al., 2012; Long et al., 2012; Sosman et al.,
2012). The downstream kinase MEK represents an additional
promising target, and combinations of both kinase
inhibitors are evaluated (Eggermont and Robert, 2011;
Flaherty et al., 2012).
For targeting the MAPK pathway at an early step, we used
here L-779,450, which was described as inhibitor for A-, B-,
and CRAF (Shelton et al., 2003). As CRAF activation upon
BRAF inhibition is discussed as a cause of resistance and
melanoma relapse (Heidorn et al., 2010; Maurer et al., 2011;
Sullivan and Flaherty, 2012), simultaneous inhibition of both
RAF isoforms may be considered as a supportive strategy. Also
other MAPKs, as p38 may be targeted by L-779,450, which
may allow a comprehensive antitumor approach (Shelton
et al., 2003). Efficient inhibition of the MAPK pathways by
L-779,450 was seen in BRAF(V600E)-mutated melanoma
cells by complete abrogation of ERK phosphorylation.
Comparably high pERK levels were also seen in BRAF-WT
cells, which were however less affected by L-779,450.
Thus, ERK phosphorylation in these cells may depend on
alternative pathways, e.g., as suggested for protein kinase
Ca (Rucci et al., 2005).
Reduced cell growth in response to L-779,450 was reported
in hematopoietic cells, which appeared as related to ARAF
and CRAF in these cells (Shelton et al., 2003). Similarly,
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melanoma cells responded with reduced cell growth to
PLX4720 (Tsai et al., 2008), and antiproliferative effects as
well as G1 arrest were also seen here by L-779,450. These
antiproliferative effects were not restricted to BRAF-mutated
melanoma cells; however, there was a correlation between
G1 arrest induced by L-779,450 and its ability to enhance
TRAIL-induced apoptosis.
TRAIL represents a promising antitumor strategy, due to
selective apoptosis induction in tumor cells (Walczak et al.,
1999; Ashkenazi, 2002), but the antitumor activity of TRAIL
receptor agonists remained only limited in clinical trials
(Herbst et al., 2010; Younes et al., 2010; Soria et al., 2011).
Non-sufficient efficacy was attributed to inducible resistance,
also seen in melanoma cells (Zhang et al., 2006; Kurbanov
et al., 2007). Overcoming TRAIL resistance thus represents
a promising therapeutic approach, and different strategies
were investigated in melanoma cells as signaling inhibitors,
chemotherapy, and UV irradiation (Ivanov et al., 2008; Berger
et al., 2011; Hornle et al., 2011; Quast et al., 2012).
Although L-779,450 hardly induced apoptosis by itself, it
efficiently enhanced TRAIL-induced apoptosis in eight of ten
melanoma cell lines, suggesting a link between RAF activation
and TRAIL resistance in melanoma cells. The relation between
active MAPK pathways and TRAIL resistance had also been
reported previously by using an inhibitor for the downstream
MAPK MEK (Zhang et al., 2003). Activation of MAPK
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to 10mM L-779,450±TRAIL (24 hours). Cells with small interfering (si)RNA-
mediated Smac knockdown (dark bars) were compared with scramble
(Scr)-siRNA-transfected controls (light gray; means and SDs of triplicate values).
Smac downregulation is shown by western blotting (inset; 24 hours, GAPDH
as control). Statistical significance of abrogated apoptosis by Smac knockdown
is indicated (*Po0.05). (a–c) At least two independent experiments revealed
comparable results. AIF, apoptosis-inducing factor; Cyt c, cytochrome c;
Dcm, mitochondrial membrane potential.
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pathways and relations to TRAIL resistance were also seen in
colon carcinoma (Oikonomou et al., 2011), and in agreement
we found enhancement of TRAIL-induced apoptosis in BRAF-
WT- and K-Ras-mutated HCT-116 colon carcinoma cells. As
also BRAF-WT and N-Ras-mutated melanoma cell lines were
sensitized for TRAIL by L-779,450, pan-RAF inhibition also
proved helpful when the pathway was activated at an
upstream step.
Enhanced activation of effector caspase-3, whereas activa-
tion of initiator caspase-8 and -9 was not further enhanced by
L-779,450, indicated the role of mitochondrial apoptosis
pathways and Smac release. Smac can activate caspase-3
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via preventing the blockage of XIAP (Chai et al., 2000). Thus,
caspase-3 was processed to its intermediate 20 kDa cleavage
product in response to TRAIL, whereas full caspase-3
processing to its mature 15 and 17 kDa cleavage products
was particularly enabled upon combination with L-779,450.
The significance of the Smac/XIAP rheostat in melanoma
apoptosis resistance was also suggested in previous studies
(Zhang et al., 2003; Hornle et al., 2011; Quast et al., 2012).
Thus, mitochondrial apoptosis pathways were activated by
L-779,450/TRAIL already after 3 hours, as seen by the release
of apoptogenic mitochondrial factors. A role of mitochondrial
pathways had also been seen in melanoma cells when
combining other signaling inhibitors with TRAIL (Zhang
et al., 2003; Berger et al., 2011; Quast et al., 2012).
XIAP is considered as a major anti-apoptotic factor in
cancer cells, which prevents caspase-3 activity (Mannhold
et al., 2010; Fulda and Vucic, 2012), and its predominant role
was demonstrated in melanoma cells (Hornle et al., 2011;
Quast et al., 2012). It may therefore also explain enhanced
apoptosis by L-779,450/TRAIL. In agreement, siRNA-mediated
knockdown largely abolished induced apoptosis. Suppression
of apoptosis by Smac knockdown was also seen in melanoma
cells, when TRAIL was combined with UVB or an ion channel
inhibitor (Hornle et al., 2011; Quast et al., 2012).
Bcl-2 proteins, which control mitochondrial pathways,
critically affected apoptosis induction by L-779,450/TRAIL.
Thus, apoptosis was abrogated in melanoma cells by Bcl-2
overexpression or Bax knockdown. The decisive role of Bax
activation was proven by Bax N-terminus-specific antibodies,
whereas the alternative pathway via Bak was not affected.
Interestingly, Bax was activated by L-779,450 treatment alone
already after 2 hours. As L-779,450 did not induce apoptosis
by itself, it only opened a gate for TRAIL sensitization, and the
switch appeared to be the Bax activation.
Apoptosis regulators may be controlled by MAPK pathways,
as upregulation of Mcl-1 and survivin or downregulation of
Bad and Bim (Ai et al., 2006; McCubrey et al., 2007; Cartlidge
et al., 2008). Whereas no significant changes were obtained
for other apoptosis regulators, the proapoptotic BH3-only
protein BimEL was significantly upregulated in melanoma
cells in response to L-779,450. Upregulation of Bim was
also reported in response to the selective BRAF inhibitor
PLX4720 (Wroblewski et al., 2013) and the MEK inhibitor
U0126 (Wang et al., 2007). Bim isoforms represent efficient
inductors of apoptosis through antagonizing all prosurvival
Bcl-2 proteins (Chen et al., 2005). The relation of Bim and
MAPKs is based on ERK-mediated Bim phosphorylation,
which triggers its proteasomal degradation (Cartlidge et al.,
2008). The critical role of Bim in sensitization of melanoma
Figure 6. Induction of Bim and autophagy. (a, b) Expression of BimEL was
determined by western blotting in Mel-HO, A-375, and A-375-TS melanoma
cells treated with 10mM L-779,450 and in A-375 and A-375-TS treated with
L-779,450±tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL). Glyceraldehyde dehydrogenase (GAPDH) served as loading control.
(c) Percentages of apoptotic cells (sub-G1) were determined in A-375 cells
with small interfering RNA (siRNA)-mediated knockdown for Bim (dark bars),
as compared with scramble (Scr)-siRNA-transfected controls (light gray).
Treatments: 10mM L-779,450±TRAIL for 24 hours. Means and SDs of
representative experiments (triplicate values) are shown. Statistical significance
is indicated (*Po0.05), when comparing Bim and scramble siRNA. (Inset) Bim
expression is shown by western blotting (24 hours), with GAPDH as loading
control. (d) Cell photographs (magnification 1:200) of TRAIL-sensitive A-375
and TRAIL-resistant A-375-TS treated with L-779,450 (10mM) are shown.
(e) Expression of light chain 3-II (LC3-II) was determined by western blotting in
A-375 and A-375-TS treated with TRAIL (20 ng ml1) and/or L-779,450 (10mM).
(a–e) At least two independent experiments revealed comparable results.
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cells for TRAIL-induced apoptosis by L-779,450 was
demonstrated here by its siRNA-mediated knockdown.
Also, induced autophagy was seen upon L-779,450 treat-
ment. Autophagy mainly represents a survival mechanism,
which may enable tumor cells to outlive limiting growth
conditions (Kondo et al., 2005; Levine, 2006). Thus,
autophagy induced by MAPK inhibition may be seen as a
response of the cells to survive the limitation caused by RAF
inhibition. Enhanced autophagy in melanoma cells was
recently also reported in response to selective BRAF
inhibitors (Kim et al., 2012). Autophagy may thus limit an
antitumor activity (Gump and Thorburn, 2011), but a possible
autophagy-mediated survival was crossed here by apoptosis
induction through TRAIL.
In conclusion, inhibition of cell proliferation and sensitiza-
tion for TRAIL-induced apoptosis are suggested here for
explaining the antitumor activity of RAF inhibitors in
melanoma. As TRAIL is expressed by cytotoxic T cells
(Brincks et al., 2011), enhancement of TRAIL sensitivity may
further support an antitumor immune response. Moreover,
TRAIL receptor agonists, which have been seen in clinical
trials, in combination with RAF inhibitors may be considered
for melanoma therapy.
MATERIALS AND METHODS
Cell culture
Experiments were performed in TRAIL-sensitive (A-375, Mel-HO,
SK-Mel-28, SK-Mel-13, and SK-Mel-147) and in permanent resistant
(Mel-2a, MeWo, and SK-Mel-103) human melanoma cell lines
(Kurbanov et al., 2005). Mel-HO and A-375 were derived from
primary tumors, whereas Mel-2a, SK-Mel-13, MeWo, SK-Mel-28,
SK-Mel-147, and SK-Mel-103 were from metastasis. Sublines with
acquired TRAIL resistance (Mel-HO-TS and A-375-TS) were derived
from selection with 100 ng ml 1 TRAIL (Kurbanov et al., 2007).
TRAIL resistance was regularly controlled in parallel to all
experiments. Other A-375 subclones had been stably transfected
with a pIRES-Bcl-2 plasmid (A-375-Bcl-2) or pIRES mock plasmid
(A-375-mock), as described previously (Raisova et al., 2001).
Parental BRAF-WT, K-Ras-mutated HCT-116 colon carcinoma cells
were derived from ATCC (Maryland, MD). The HCT-116 Bax knock-
out, Bak knockdown, and Bax/Bak double knockdown cells were
kindly provided by B Vogelstein (John Hopkins Cancer Center,
Baltimore, MD) and had been described previously (Gillissen et al.,
2010). Cells were cultivated at 37 1C, 5% CO2 in DMEM (4.5 g l
 1
glucose; Gibco, Invitrogen, Karlsruhe, Germany) with 10% fetal calf
serum (FCS) and antibiotics (Biochrom, Berlin, Germany). TRAIL-
selected cells were continuously kept with 5 ng ml 1 TRAIL until
24 hours before treatment. Cells were plated in 6-, 24-, or 96-well
plates with 2 105, 5 104, and 5 103 cells, respectively, and
treatment started after 24 hours.
For induction of apoptosis, TRAIL (Alexis, Gruenberg, Germany;
ALX-201-073-C020; 20 ng ml 1), the pan-RAF inhibitor L-779,450
(Merck, Darmstadt, Germany; 0.1–50mM), the MEK inhibitor
U0126 (Sigma-Aldrich, Taufkirchen, Germany; 20mM), and the
selective BRAF(V600E) inhibitor vemurafenib/PLX4032 (Selleck
Chemicals, Houston, TX) were used. For caspase inhibition,
cells were preincubated for 1 hour with 10mM of Q-VD-OPh (MP
Biomedicals, Solon, OH).
Cell proliferation, apoptosis, and cytotoxicity
For continuous monitoring cell growth, the xCELLigence system
(Roche Diagnostics, Penzberg, Germany) was applied. Relative cell
indices correspond to attached cell numbers. Cell cycle analyses
were performed for quantification of apoptosis and cell cycle arrest
(Riccardi and Nicoletti, 2006). Cells harvested by trypsinization were
stained for 1 hour with propidium iodide (Sigma-Aldrich;
200 mg ml 1), and sub-G1 fractions, corresponding to cells with
fragmented DNA, were quantified by flow cytometry (FACS Calibur;
BD Bioscience, Bedford, MA). Cytotoxicity was determined according
to the release of lactate dehydrogenase by damaged cells into the
culture supernatants. Values of non-treated cells were set to 1, and
data were calculated as relative values of the non-treated controls
(Cytotoxicity detection assay; Roche Diagnostics).
Mitochondrial membrane potential was determined with the
fluorescent dye tetramethylrhodamine methyl ester perchlorate
Sigma-Aldrich; 1 mM (TMRMþ ; Sigma-Aldrich; 1 mM). Cells harvested
by trypsinization were stained for 15 min at 37 1C and analyzed by
flow cytometry.
For identification of chromatin condensation and nuclear fragmen-
tation in course of apoptosis, cells were harvested by trypsinization,
centrifuged on cytospins, and fixed for 30 minutes in 4% formalde-
hyde. Cytospins were stained with bisbenzimide (Hoechst-33258;
Sigma-Aldrich; 1 mg ml 1, 30 minutes) and examined by fluores-
cence microscopy. Apoptotic cells were identified by fragmented
nuclei or by bright blue-stained nuclei with condensed chromatin.
Assays for Bax/Bak activation
For analysis of Bax and Bak conformational changes related to their
activation, primary antibodies specific for the N-terminal domains of
Bax or Bak were applied in flow cytometry (Bax-NT, 1:100 (Upstate,
Lake Placid, NY; no. 06-499); Bak-NT (Merck, Darmstadt, Germany),
AM04, 1:10). The N-terminal domains become accessible in course
of Bax/Bak activation (Gillissen et al., 2007; Martinou and Youle,
2011). Cells (105) were harvested by trypsinization and fixed for
30 minutes with 4% paraformaldehyde in phosphate-buffered saline.
Cells were then incubated with the respective antibodies for 1 hour at
4 1C in phosphate-buffered saline/1% FCS, which also contained
0.1% saponin for cell permeabilization. Cells were subsequently
incubated for 1 hour at 4 1C in the dark with the secondary antibody
goat anti-rabbit IgG (Hþ L)-FITC (Jackson Immuno Research, West
Grove, FL). After washing and resuspension in phosphate-buffered
saline/1% FCS, cells were immediately measured by flow cytometry.
Cell transfection with siRNA
Transient cell transfection was performed in 6-well plates at 24 hours
after seeding (70% confluence). Treatment with L-779,450/TRAIL
followed after another 24 hours. Amounts of 20 pmol siRNA and 4ml
TurboFect (Fermentas, St Leon-Rot, Germany) were used per well.
The siRNAs for Smac (sc-36505), Bax (sc-29212), Bak (sc-29786),
Bim (sc-29802), and the scrambled control (sc-37007) were derived
from Santa Cruz Biotechnology (Santa Cruz, CA).
Protein analysis
For western blotting, total protein extracts were obtained by cell lysis in
150 mM NaCl, 1 mM EDTA, 2 mM phenylmethyl sulfonyl, 1 mM leu-
peptin, 1 mM pepstatin, 0.5% SDS, 0.5% NP-40, and 10 mM Tris-HCl
(pH 7.5). Cytosolic and mitochondrial cell fractions were prepared by a
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kit of PromoKine (Heidelberg, Germany). Western blotting on nitro-
cellulose membranes was described previously (Eberle et al., 2003).
Primary antibodies obtained were as follows: cleaved caspase-3
(3664, rabbit, 1:5,000), caspase-3 proform (9662, rabbit, 1:1,000),
caspase-8 (9746, mouse, 1:1,000), caspase-9 (9505, rabbit, 1:1,000),
ERK (4695, rabbit, 1:2,000), pERK (9101, rabbit, 1:2,000), and XIAP
(2042, rabbit, 1:1,000) from Cell Signaling; Bcl-2 (sc-783, rabbit;
1:200), Bax (sc-493, rabbit, 1:200), Bak (sc-893, rabbit, 1:500), AIF
(sc-9416, goat, 1:1,000), Smac (sc-56230, mouse, 1:1,000), Bim (sc-
11425, rabbit, 1:400), light chain 3 (sc-292354, rabbit, 1:500), Bid
(sc-2002, rabbit, 1:1,000), glyceraldehyde dehydrogenase (GAPDH)
(sc-3233, mouse, 1:1,000), and survivin (sc-17779, mouse, 1:500)
from Santa Cruz Biotechnology. The antibodies used further were:
cytochrome c (no. 556433, mouse, 1:1,000; BD Biosciences, Heidel-
berg, Germany) and VDAC (voltage-dependent anion channels; anti-
porin 31HL, 529536, mouse, 1:500; Calbiochem, Darmstadt, Ger-
many). The secondary antibodies used were as follows: peroxidase-
labeled goat anti-rabbit, goat anti-mouse, and rabbit anti-goat (Dako,
Hamburg, Germany; 1:5,000).
Statistical analyses
Assays consisted of triplicates, and at least two independent experi-
ments were performed. Mean values and SDs were calculated either
by enclosing all individual values of the independent experiments (at
least six values) or a representative experiment is shown (triplicate
values). Statistical significance was proven by Student’s t-test in case
of normal distribution, and P-values of o0.05 were considered as
statistically significant.
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